General Biologic
集博使命: 為客戶評估、把握以及開拓生物技術產業內的寶貴機遇,傳播卓越、進取、創新的文化。
集博客戶: 包括投資商、醫藥公司、生物技術公司,以及科研儀器、試劑和耗材的供應商。
集博服務: 包括管理咨詢、投資融資服務、投資管理以及撰寫并出版行業分析報告。
集博團隊:集博員工具有多年在中美生物技術/醫藥行業工作的經驗,多數擁有生命科學領域碩士或博士學歷。
Matthew Chervenak 是集博公司的總裁及創立者。他曾在美國衛生院(NIH)牙科研究所、美國眼科研究所以及紐約大學醫學中心從事分子生物學研究,隨后在世界著名咨詢公司Sapient Corporation擔任戰略咨詢顧問,專門為紐約的小型企業以及投資銀行提供服務。2002年,Chervenak創立了集博公司。
公司性質: 集博(上海集博投資管理咨詢有限公司)是一家外商獨資企業,這一身份使我們可以便利地為國內外的客戶提供服務。
GB’s clients include industry participants and investors engaged in the pharmaceutical, biotechnology and healthcare industries.
Our team:
Our multidisciplinary team includes Chinese and Westerners with industry and scientific backgrounds. The mix of business and science, East and West, makes us a truly unique firm in the marketplace. Our dedication to excellence, learning, and innovation creates an exceptional work environment.
Matthew Chervenak is president and founder of GB. His scientific experience includes molecular biology research at the National Institute of Dental Research, the National Eye Institute, and New York University Medical Center. He has worked as a strategy consultant at Sapient Corporation serving startup and investment banking clients in New York City. He founded GB in 2002.
Structure within China:
GB (Shanghai GB Investment Management Consulting Co. Limited) is a Wholly Owned Foreign Enterprise in China.
?